Vaccines
Concerns over vaccination links to heart inflammation are valid, a U.S. Centers for Disease Control and Prevention advisory committee announced this afternoon.
The two companies will assess the safety and immunogenicity of the vaccine candidate, which codes for the hemagglutinin protein in the A/H3N2 strain of the seasonal flu virus.
Cuba’s Abdala vaccine is 92% effective against the novel coronavirus, according to a recent analysis of late-stage trials.
Please check out the biopharma industry’s COVID-19 stories that are trending for June 22, 2021.
Though the world is reopening, this pandemic is not over. Moderna continues expanding production to answer the call globally.
The new findings likely throw a wrench in the company’s plans to deliver millions of much-needed vaccine doses to the European Union soon.
A recent study conducted by Public Health England found that the available vaccines were “highly effective” at preventing hospitalization after two doses.
The study also found the vaccine was 100% effective at preventing moderate and severe disease.
The EMA identified a rare blood condition, capillary leak syndrome, as a potential side effect of AstraZeneca’s Vaxzevria.
Half of these doses will be shared by the U.S., while the U.K. has committed another 100 million shots.
PRESS RELEASES